4-Fluorophenylundecanoyl-alpha-galactosylceramide [7DW8-5]

AdipoGen Life Sciences

4-Fluorophenylundecanoyl-alpha-galactosylceramide [7DW8-5]

10

Research Use Only

>95%

C41H72FNO9

742

Chemical. CAS: 1056025-00-3. Formula: C41H72FNO9. MW: 742. . Glycolipid derivative of alpha-GalCer. Potent stimulator of invariant natural killer T (iNKT) cells (140-fold lower EC50 compared to alpha-GalCer). Specific ligand (strongest binding affinity) of the lipid-binding MHC class I-like protein CD1d in human and mouse NKT cells with. Show to induce secretion of key cytokines such as IFN-gamma and IL-12, and activate autologous dendritic cells, as well as binding to CD1d and the invariant T cell receptor (invTCR). Potent vaccine adjuvant (~100 times stronger than alpha-GalCer) that can harness and amplify the immunotherapeutic potential of NKT cells to treat certain microbial infections such as malaria and HIV. Potential immunotherapeutic to treat cancer, infectious diseases and autoimmune diseases. - Glycolipid derivative of alpha-GalCer. Potent stimulator of invariant natural killer T (iNKT) cells (140-fold lower EC50 compared to alpha-GalCer). Specific ligand (strongest binding affinity) of the lipid-binding MHC class I-like protein CD1d in human and mouse NKT cells with. Show to induce secretion of key cytokines such as IFN-gamma and IL-12, and activate autologous dendritic cells, as well as binding to CD1d and the invariant T cell receptor (invTCR). Potent vaccine adjuvant (~100 times stronger than alpha-GalCer) that can harness and amplify the immunotherapeutic potential of NKT cells to treat certain microbial infections such as malaria and HIV. Potential immunotherapeutic to treat cancer, infectious diseases and autoimmune diseases.

O[C@H]1[C@@H](O)[C@@H](CO)O[C@H](OC[C@@H]([C@@H]([C@@H](CCCCCCCCCCCCCC)O)O)NC(CCCCCCCCCCC2=CC=C(F)C=C2)=O)[C@@H]1O

-20°C,2°C to 8°C

12352200